For fifteen years, researchers at Brazil's Butantan Institute have pursued a single-dose answer to one of the tropics' most persistent threats. Now, as dengue claims lives and overwhelms health systems across Brazil in early 2024, that answer stands at the threshold of regulatory approval — a moment when science, urgency, and institutional capacity converge in ways that rarely align so clearly. The institute plans to submit its application to ANVISA by July, offering not only a tetravalent vaccine with strong efficacy data, but the manufacturing scale to deliver it to a nation that can no long
TNH1
· Feb 01, 2024
· health
· 4 min de lectura
High
Verificación: Verificado
Butantan to seek dengue vaccine approval by July after final trial phase
Brazil recorded 243,721 probable dengue cases with 24 confirmed deaths and 163 under investigation in early 2024, with increased risk of severe dengue from reinfection.
◉
Health & Medicine
2834 artículos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% coincidencia
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% coincidencia
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% coincidencia
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% coincidencia
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% coincidencia
Cobertura Relacionada
Folha de S.Paulo · Aug 26
Ônibus escolar cai em ribanceira e deixa duas crianças feridas em SC
Ônibus escolar com dez crianças caiu dez metros em ribanceira em Santa Catarina. Duas crianças ficaram feridas e foram h…
G1 · Aug 26 Incêndio em hospital do Paquistão mata ao menos 15 bebêsPelo menos 15 recém-nascidos morreram em incêndio no hospital PIMS em Islamabad, causado por falha no sistema de ar-cond…
G1 · Aug 26 Zelador agredido com paulada evolui na UTI, mas segue internado no DFZelador agredido há 15 dias por homem em situação de rua apresenta melhora clínica na UTI, respondendo a estímulos e com…
Google News · Aug 26 Diretor do Atlético-MG acusa Kaio Jorge de 'maldade e deslealdade' após lance polêmicoDirigente do Atlético-MG acusa Kaio Jorge de jogada maldosa e desleal que resultou em queda do zagueiro Ruan Tressoldi, …
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
Brazil's Butantan Institute seeks regulatory approval for a single-dose tetravalent dengue vaccine by July, positioning itself competitively against Japan's Takeda in the global vaccine market.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Southeast Asia
Global dengue-endemic regions
Brazil strengthens its regional pharmaceutical sovereignty and positions itself as a vaccine producer competing with Japanese and Western manufacturers. Success would enhance Brazil's soft power in global health and reduce dependency on foreign vaccine imports, particularly relevant given Latin America's dengue burden.
Similar to India's vaccine diplomacy through generic drug production, Brazil leverages Butantan's regional manufacturing capacity to establish itself as a trusted vaccine supplier for the Global South, challenging traditional Western pharmaceutical dominance.
Lente Económico
📈
Brazil's Butantan Institute seeks ANVISA approval by July for a single-dose tetravalent dengue vaccine, positioning itself competitively against Takeda's two-dose alternative in a growing vaccine market.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and vaccine manufacturing
Healthcare and public health
Biotechnology
Medical devices and diagnostics
Brazilian consumers and patients gain access to a potentially more convenient single-dose dengue vaccine option, reducing healthcare visits and improving vaccination compliance rates. Public health expenditure may decrease through lower administration costs and improved vaccination coverage.
ANVISA regulatory approval expected mid-2024 could establish Brazil as a competitive vaccine producer in Latin America. Success may prompt government procurement policies favoring domestic production, potentially reducing vaccine import dependency. International trade implications for vaccine distribution across LATAM region.